Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORA trial of docetaxel versus docetaxel + radium-223 in metastatic castration-resistant prostate cancer
NL-OMON59897Phase 3Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Docetaxel with Docetaxel + radium-223 dichloride (2 arms). Primary endpoint: Overall survival. Started Jan 2019; status: active, not recruiting.
02
Drugs
radium-223 dichloridedocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON59897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59897.